Among the highlights, detectors maker Paraytec, where Braveheart bought the remaining shares it did not already own in October, has begun the second round of end-user trials for its main R&D project, with the scientific team due to visit GlaxoSmithKline and Medimmune over the coming weeks, having already conducting trials with Fujifilm Diosynth.
The trial, which is being funded by a Innovate UK grant, is focused on the measuring of protein aggregation in biopharmaceuticals, an impurity that it is crucial for drug companies to control.
Meanwhile, Pharm 2 Farm (P2F), where Braveheart upped its stake from 33.33% to 51.72% in December to help the business open a new manufacturing facility and expand its sales team, has received “significant interest” from the turf management industry after a recent trade show.
At P2F, which has developed nanoparticle technology to improve plant feeds, Braveheart highlighted product sales to customers in the Australian hydroponics market.
Elsewhere, Kirkstall, which is 65%-owned by Braveheart, has recently appointed new distributors in South Korea and China to sell its Quasi Vivo system for cell and tissue culture in laboratories, and is preparing for its annual Advances in Cell and Tissue Culture conference in June.
Gyrometric Systems, where Braveheart owns 20% and most of the rest is owned by AIM-listed Remote Monitored Systems, there are plans to shortly begin selling its new timing laser product that can be used to monitor the speed of rotating shafts, adding to a suite of products that was broadened by the “significant breakthrough” last year of its Absolute Dynamic Shaft Alignment system.
As Remote Monitored Systems said in December, revenues at GyroMetric remain modest but “considerable progress” has been made in expanding the customer base.
Braveheart said Phasefocus, of which it owns 21%, has added distribution agreements in Italy, Canada, Japan, France and Israel in recent months, which are expected to drive sales growth in its Livecyte live cell analysis product line.
Over at 38%-owned Sentinel Medical, work continues with the University of Sheffield to optimise the test protocols before re-starting the testing of bladder cancer patient samples after a decision was taken to revise them after the initial trials.